再発および/または難治性多発性骨髄腫の参加者における実際の現在の標準治療に関する研究 (MoMMent)
再発および/または難治性多発性骨髄腫患者における実際の現在の標準治療に関する前向き多国籍研究
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.
調査の概要
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Bristol、イギリス、BS10 5NB
- Southmead Hospital
-
London、イギリス、NW1 2PG
- University College Hospital
-
London、イギリス、SE5 9RS
- Kings College Hospital
-
London、イギリス、SW17 OQT
- St Georges Hospital
-
Maidstone、イギリス、ME16 9QQ
- Maidstone Hospital
-
Nottingham、イギリス、NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Surrey、イギリス、SM2 5PT
- The Royal Marsden NHS Trust Sutton
-
-
-
-
-
Bari、イタリア、70124
- U.O. Ematologia Istituto Tumori Giovanni Paolo II
-
Bari、イタリア、70124
- Oncologia Medica - Irccs - Istituto Tumori Giovanni Paolo II
-
Bologna、イタリア、40138
- Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi
-
Catania、イタリア、95128
- Policlinico di Catania
-
Civitanova Marche、イタリア、62012
- Ospedale Civile di Civitanova Marche
-
Genova、イタリア、16132
- Ospedale Policlinico San Martino IRCCS
-
Genova、イタリア、16132
- IRCCS Azienda Ospedaliera San Martino - IST
-
Lecce、イタリア、73100
- Ospedale Vito Fazzi
-
Meldola、イタリア、47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Padova、イタリア、35128
- Universita degli Studi di Padova Azienda Ospedaliera di Pa
-
Palermo、イタリア、90146
- Ospedale Villa Sofia-Cervello
-
Pavia、イタリア、27100
- Fondazione IRCCS Policlinico San Matteo
-
Pescara、イタリア、65124
- Presidio Ospedaliero Pescara
-
Reggio Calabria、イタリア、89124
- Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria
-
Roma、イタリア、00168
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Roma、イタリア、128
- Campus Bio Medico di Roma
-
Roma、イタリア、00161
- Università di Roma La Sapienza
-
San Giovanni Rotondo、イタリア、71013
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
San Giovanni Rotondo、イタリア、71013
- Casa Sollievo Della Sofferenza IRCCS
-
Tricase、イタリア、73039
- Ospedale Cardinale G. Panico
-
Vicenza、イタリア、36100
- Azienda Ulss 8 Berica- Ospedale Di Vicenza
-
-
-
-
-
Amsterdam、オランダ、1081 HV
- VU Medisch Centrum
-
Groningen、オランダ、9713 GZ
- UMCG
-
-
-
-
-
Leoben、オーストリア、8700
- LKH Leoben
-
Vienna、オーストリア、1060
- Krankenhaus der barmherzigen Schwestern
-
-
-
-
-
Alexandroupoli、ギリシャ、68100
- University Hospital of Alexandroupolis
-
Athens、ギリシャ、115 26
- Henry Dunant Hospital Center
-
Athens、ギリシャ、115 28
- Alexandra Hospital
-
Athens、ギリシャ、115 27
- Laiko General Hospital Of Athens 1
-
Athens、ギリシャ、115 27
- Laiko General Hospital of Athens 2
-
Piraeus、ギリシャ、18537
- Metaxa Cancer Center Hospital Of Piraeus
-
Rio、ギリシャ、265 04
- General University Hospital of Patras
-
Thessaloniki、ギリシャ、546 39
- Anticancer Hospital of Thessaloniki Theageneio
-
Thessaloniki、ギリシャ、54636
- Ahepa University General Hospital of Thessaloniki
-
-
-
-
-
Chur、スイス、7000
- Kantonsspital Graubunden
-
Winterthur、スイス、8400
- Kantonsspital Winterthur, Medizinische Onkologie
-
Zurich、スイス、8091
- Universitatsspital Zurich
-
Zurich、スイス、8032
- Hirslanden Klinik Hirslanden
-
-
-
-
-
Barcelona、スペイン、08908
- Inst. Cat. Doncologia-H Duran I Reynals
-
Gijón、スペイン、33394
- Hosp. de Cabuenes
-
Granada、スペイン、18014
- Hosp. Univ. Virgen de Las Nieves
-
Jerez de la Frontera、スペイン、11407
- Hosp. de Jerez de La Frontera
-
León、スペイン、24008
- Hosp. de Leon
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28034
- Hosp. Univ. Ramon Y Cajal
-
Palma、スペイン、7120
- Hosp. Univ. Son Espases
-
Pamplona、スペイン、31008
- Clinica Univ. de Navarra
-
Salamanca、スペイン、37007
- Hosp Clinico Univ de Salamanca
-
Santander、スペイン、39008
- Hosp. Univ. Marques de Valdecilla
-
Santiago de Compostela、スペイン、15706
- Hosp. Clinico Univ. de Santiago
-
Valencia、スペイン、46010
- Hosp. Clinico Univ. de Valencia
-
Valencia、スペイン、46017
- Hosp. Univ. Dr. Peset
-
Valladolid、スペイン、47003
- Hosp. Clinico Univ. de Valladolid
-
Zaragoza、スペイン、50009
- Hosp. Univ. Miguel Servet
-
-
-
-
-
Berin、ドイツ、12203
- Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
-
Cologne、ドイツ、50397
- Universitaetsklinikum Koeln
-
Dresden、ドイツ、01307
- Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden
-
Hamburg、ドイツ、20251
- Universitätsklinik Hamburg-Eppendorf - Orthopädische Universitätsklinik und Poliklinik
-
Hamm、ドイツ、59073
- St. Barbara-Klinik Hamm GmbH
-
Heidelberg、ドイツ、69120
- Universitaetsklinikum Heidelberg
-
Karlsruhe、ドイツ
- Staedtisches Klinikum Karlsruhe gGmbH
-
Leipzig、ドイツ、4103
- Universitaetsklinikum Leipzig
-
Leipzig、ドイツ、04103
- MVZ Mitte-Onkologische Schwerpunktpraxis
-
Tübingen、ドイツ、72076
- Klinikum der Eberhard Karls Universitaet Abt fur innere Med II Haematologie Onkologie Germany
-
Würzburg、ドイツ、97080
- Universitatsklinikum Wurzburg
-
Zwickau、ドイツ、08060
- Heinrich-Braun-Klinikum gGmbH
-
-
-
-
-
Lille、フランス、59037
- CHRU de Lille Hopital Claude Huriez
-
Montpellier、フランス、34295
- CHU de Montpellier Hopital Saint Eloi
-
Nantes、フランス、44093
- CHU de Nantes hotel Dieu
-
Pierre-Bénite、フランス、69495
- Centre hospitalier Lyon-Sud
-
Toulouse、フランス、31059
- Pôle IUC Oncopole CHU
-
-
-
-
-
Edegem、ベルギー、2650
- UZ Antwerpen
-
Genk、ベルギー、3600
- Ziekenhuis Oost-Limburg
-
Leuven、ベルギー、3000
- UZ Leuven
-
Mons、ベルギー、7000
- Chu Helora Hospital De Mons Site Kennedy
-
Sint-Niklaas、ベルギー、9100
- Vitaz
-
Yvoir、ベルギー、5530
- Ucl de Mont-Godinne
-
-
-
-
-
Chaves、ポルトガル、5400 482
- Ulstmad - Hosp. Chaves
-
Coimbra、ポルトガル、3004 561
- Uls Coimbra - Hosp. Univ. Coimbra
-
Porto、ポルトガル、4200 319
- Uls Sao Joao - Hosp. Sao Joao
-
-
-
-
-
Bucharest、ルーマニア、022328
- Fundeni Clinical Institute
-
Bucharest、ルーマニア
- Spitalul Clinic Coltea, Clinica Hematologie
-
Cluj-Napoca、ルーマニア、400015
- Institutul Oncologic Prof Dr. Ion Chiricuta Cluj Napoca 1
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population consists of participants with previously treated multiple myeloma, having received standard of care (SOC) antimyeloma treatments during local clinical practices.
説明
Inclusion Criteria:
- For Period 1 and 2: Have a documented diagnosis of multiple myeloma according to International myeloma working group (IMWG) diagnostic criteria. For Period 3: Start of talquetamab for the treatment of a documented diagnosis of relapsed and/or refractory multiple myeloma (RRMM) according to IMWG diagnostic criteria and the approved indication. The decision to start talquetamab must be made independently of the decision to participate in the study, with the start of treatment occurring up to 28 days following the start of screening or having occurred up to 21 days before the informed consent form (ICF) date
- For Period 1 and 2: Have an Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1. For Period 3: Have ECOG performance status of 0,1 or 2
- For Period 1,2 and 3: Must not be pregnant or must not plan to become pregnant within the study period
- For Period 1,2 and 3: Participants must sign an ICF indicating that he or she understands the purpose and observational nature of the study and is willing to participate. Consent is to be obtained prior to the initiation of any study-related data collection
- For Period 1 and 2: Received at least 3 prior lines of therapy (induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen). Undergone at least 1 complete cycle of treatment for each line of therapy, unless progressive disease (PD) was the best response to the line of therapy
- For Period 1 and 2: Must have documented evidence of progressive disease based on participating physician's determination of response by the IMWG response criteria on or after the last regimen. Participants with documented evidence of progressive disease within the previous 6 months and who are refractory or non-responsive to their most recent line of treatment afterwards are also eligible
- For Period 1 and 2: Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level 1.0 g/dL or urine M-protein level 200 mg/24 hours; or Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Period 1: Received as part of previous therapy a PI, an IMiD, and an anti-CD38 antibody (prior exposure can be from different monotherapy or combination regimens)
- Period 2: Received as part of previous therapy a PI, an IMiD, an anti-CD38 antibody, and BCMA-targeted therapy (prior exposure can be from different monotherapy or combination regimens)
- For period 3: At least one of the following prior to the start of talquetamab: a. Measurable disease at screening as defined by any of the following: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) or urine M-protein level >= 200 milligram (mg) /24 hours; or b. serum immunoglobulin free light chain >= 10 milligrams per deciliter (mg/dL) and abnormal ratio of involved and uninvolved free light chains or c. presence of bone lesions or plasmacytomas (>=1 lesion has 2 diameters >= 1 centimeter [cm])
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Participants with Relapsed/Refractory Multiple Myeloma
Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant. |
There is no interventional treatment component for participants with RRMM in this study. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response Rate (ORR)
時間枠:Up to 52 months
|
Overall Response Rate is defined as the percentage of participants who achieve a partial response (PR) or better response according to the International Myeloma Working Group (IMWG) response criteria, as assessed by Response Review Committee (RRC). |
Up to 52 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Very Good Partial Response (VGPR) Rate
時間枠:Up to 52 months
|
VGPR rate is defined as the percentage of participants who achieve a VGPR or better response according to IMWG response criteria. |
Up to 52 months
|
|
Complete Response (CR) Rate
時間枠:Up to 52 months
|
CR rate is defined as the percentage of participants who achieve a CR or better response according to IMWG response criteria. |
Up to 52 months
|
|
Stringent Complete Response (sCR) Rate
時間枠:Up to 52 months
|
sCR rate is defined as the percentage of participants who achieve a sCR according to IMWG response criteria. |
Up to 52 months
|
|
Minimal Residual Disease (MRD) Negative Rate
時間枠:Up to 52 months
|
MRD negative rate is defined as the percentage of participants with negative MRD status according to IMWG response criteria. |
Up to 52 months
|
|
Clinical Benefit Rate (CBR)
時間枠:Up to 52 months
|
CBR is defined as the percentage of participants with clinical benefit. CBR=ORR (sCR + CR + VGPR + PR) + minimal response (MR). |
Up to 52 months
|
|
Duration of Response (DOR)
時間枠:Up to 52 months
|
DOR is defined as time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease as defined in the IMWG criteria. |
Up to 52 months
|
|
Time to Response (TTR)
時間枠:Up to 52 months
|
TTR is defined as the time between the date of Day 1 of Cycle 1 and the first clinical response evaluation that the participant has met all criteria for PR or better response. |
Up to 52 months
|
|
Time to Best Response
時間枠:Up to 52 months
|
Time to best response is defined as the time between the date of Day 1 of Cycle 1 and best objective response. |
Up to 52 months
|
|
Time to Next Treatment (TTNT)
時間枠:Up to 52 months
|
TTNT is defined as the time from diagnosis to the start of the next-line treatment. |
Up to 52 months
|
|
Progression-free Survival (PFS)
時間枠:Up to 52 months
|
PFS is defined as the time from the date of Day 1 of Cycle 1 to the date of first documented disease progression (as defined in the IMWG response criteria) or death due to any cause, whichever occurs first. |
Up to 52 months
|
|
Time to Progression on the Next Line of Subsequent Antimyeloma Therapy or Death, Whichever Occurs First (PFS2)
時間枠:Up to 52 months
|
PFS2 is defined as the time from the date of Day 1 of Cycle 1 to progression on the next line of subsequent antimyeloma therapy or death, whichever occurs first. |
Up to 52 months
|
|
Overall Survival (OS)
時間枠:Up to 52 months
|
OS is the duration from the date of Day 1 of Cycle 1 to the date of the participant's death or study completion, whichever occurs first. |
Up to 52 months
|
|
Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
時間枠:Baseline up to 52 months
|
The EORTC-QLQ-C30 Version 3 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
Baseline up to 52 months
|
|
Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
時間枠:Baseline up to 52 months
|
The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Baseline up to 52 months
|
|
Period 1 and 2: Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EORTC QLQ-IL39
時間枠:Baseline up to 52 months
|
EORTC QLQ-IL39 (four single items from the EORTC QLQMY20) will be performed to assess emotional health status (feel restless or agitated, thinking about your illness, worried about dying, worried about health in the future) on scale of 1 (not at all) to 4 (very much). |
Baseline up to 52 months
|
|
Number of Participants with Adverse Events (AEs)
時間枠:Up to 52 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 52 months
|
|
Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
時間枠:Up to 52 months
|
Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening consequences; Grade 5: Death related to adverse event. |
Up to 52 months
|
|
Period 3: Number of Participants Reporting Oral Toxicities Using Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
時間枠:Up to 52 months
|
PRO-CTCAE consist of 1-8 questions of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. The following items were selected for inclusion for patients with multiple myeloma: nausea, vomiting, diarrhea, shortness of breath, rash, dizziness, headache, taste changes, and fatigue/tiredness/lack of energy. |
Up to 52 months
|
|
Period 3: Number of Participants Reporting Oral Toxicity Symptoms Using the Epstein Taste Survey (ETS)
時間枠:Up to 52 months
|
The Epstein Taste Survey consists of 17 items from the full 71 item PRO instrument, specific to taste changes. Developed for use in patients with head and neck cancer. |
Up to 52 months
|
|
Period 3: Percentage of Participants with Overall Response to Subsequent Therapies
時間枠:Up to 52 months
|
Overall Response Rate is defined as the percentage of participants who achieve a partial response (PR) or better response according to the International Myeloma Working Group (IMWG) response criteria, as assessed by Response Review Committee (RRC). Overall response for subsequent therapies, including BCMA-targeted therapies after treatment with talquetamab will be reported. |
Up to 52 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Pharmaceutica N.V., Belgium Clinical Trial、Janssen Pharmaceutica N.V., Belgium
出版物と役立つリンク
一般刊行物
- Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez-Lopez J, Rodriguez-Otero P, Dytfeld D, Diels J, Strulev V, Haddad I, Renaud T, Ammann E, Cabrieto J, Perualila N, Gan R, Zhang Y, Parekh T, Albrecht C, Weisel K, Mateos MV. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther. 2024 Apr;41(4):1576-1593. doi: 10.1007/s12325-024-02797-x. Epub 2024 Feb 24.
- Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk NWCJ, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.
- Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, Perrot A, Goldschmidt H, van de Donk NWCJ, Ocio EM, Martinez Lopez J, Rodriguez-Otero P, Dytfeld D, Jakubowiak A, Schinke C, Besemer B, Anguille S, Manier S, Rasche L, Teipel R, Scheid C, Pawlyn C, Cavo M, Diels J, Ghilotti F, Lau BW, Renaud T, Orel O, Ong F, Ramos DF, Ammann E, Parekh T, Albrecht C, Weisel K, Mateos MV. Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent. Adv Ther. 2026 Jan;43(1):333-355. doi: 10.1007/s12325-025-03409-y. Epub 2025 Nov 28.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CR109118
- 64407564MMY4001 (その他の識別子:Janssen Research & Development, LLC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。